Komori
Business alliance3744SIOS CorporationInformation and Communications, Services and Others

Notice of the Execution of a Business Partnership Agreement with Kitazato Corporation for the Joint Development of an Advanced AI-Powered Infertility Treatment Support System

サイオステクノロジー and 北里 have executed a business alliance agreement to jointly develop an AI system supporting infertility treatment. 北里 will be responsible for medical and sales activities, while サイオステクノロジー will handle AI and system development and operations.

Worth reading
48Recurring
Scored from 3 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business alliance
3744SIOS Corporation
Alliance partner株式会社北里
Details of the alliance
  1. 1

    Role of 北里: Provide advanced expertise and clinical perspectives in the medical, reproductive, and biological fields, particularly medical devices and reagents for infertility treatment.

  2. 2

    Role of 北里: Provide the data and environments used for AI training, experimentation, and validation.

  3. 3

    Role of 北里: Define the requirements for products and services based on the above.

  4. 4

    Role of 北里: Conduct sales and marketing activities targeting medical institutions and other customers, and provide customer support based on its specialized expertise.

  5. 5

    Role of サイオステクノロジー: Design, develop, and build applications and systems using IT technology.

  6. 6

    Role of サイオステクノロジー: Develop advanced algorithms and models using its expertise in the medical field and research成果 related to medical AI.

  7. 7

    Role of サイオステクノロジー: Operate, maintain, and revise systems and applications, including infrastructure.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionSpecializes in reproductive engineering technologies for artificial insemination and in vitro fertilization, cell cryopreservation, and regenerative medicine; develops and manufactures products supporting infertility treatment and supplies its products to approximately 110 countries and regions worldwide.
Contract Date3 August 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partner株式会社北里
Alliance partner's business activitiesSpecializes in reproductive engineering technologies for artificial insemination and in vitro fertilization, cell cryopreservation, and regenerative medicine; develops and manufactures products supporting infertility treatment and supplies its products to approximately 110 countries and regions worldwide.
Type of allianceBusiness alliance
Details of the allianceRole of 北里: Provide advanced expertise and clinical perspectives in the medical, reproductive, and biological fields, particularly medical devices and reagents for infertility treatment., Role of 北里: Provide the data and environments used for AI training, experimentation, and validation., Role of 北里: Define the requirements for products and services based on the above., Role of 北里: Conduct sales and marketing activities targeting medical institutions and other customers, and provide customer support based on its specialized expertise., Role of サイオステクノロジー: Design, develop, and build applications and systems using IT technology., Role of サイオステクノロジー: Develop advanced algorithms and models using its expertise in the medical field and research成果 related to medical AI., Role of サイオステクノロジー: Operate, maintain, and revise systems and applications, including infrastructure.
Contract Date3 August 2026
Items this document does not state (18)
Alliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The parties will combine 北里's expertise in infertility treatment with サイオステクノロジー's AI analytics technology to support the work of medical professionals involved in infertility treatment, reduce reliance on individual expertise, shorten work hours, and improve pregnancy and live birth rates.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Execution of a Business Partnership Agreement with Kitazato Corporation for the Joint Development of an Advanced AI-Powered Infertility Treatment Support System | SIOS Corporation (3744) timely disclosure | Komori